A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Cannabidiol (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Botanix Pharmaceuticals
- 06 Feb 2019 Planned initiation date changed from 26 Jan 2016 to 13 Feb 2019.
- 30 Jan 2019 Status changed from planning to not yet recruiting.
- 23 Jul 2018 According to a Botanix Pharmaceuticals media release, preparation is underway for this Phase II trial.